MBX Biosciences (MBX) Net Income towards Common Stockholders (2023 - 2026)

MBX Biosciences has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$23.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 1.52% year-over-year to -$23.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$86.6 million (down 17.89% YoY) and the FY2025 annual result came in at -$87.0 million, down 40.45% from the prior year.
• Net Income towards Common Stockholders eased to -$23.5 million in Q1 2026 per MBX's latest filing, from -$22.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$8.8 million in Q4 2023 and troughed at -$23.9 million in Q1 2025.
• A 4-year average of -$17.4 million and a median of -$18.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders sank 93.56% in 2025, then gained 1.52% in 2026.
• Over 4 years, Net Income towards Common Stockholders stood at -$8.8 million in 2023, then sank by 76.25% to -$15.6 million in 2024, then slumped by 41.55% to -$22.1 million in 2025, then fell by 6.6% to -$23.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$23.5 million, -$22.1 million, and -$21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.